

From: Tull, Lori
Sent: Thursday, September 10, 2015 1:29 PM
To: Wouter Van't Hof (wvanthof@clevelandcordblood.org)
Cc: Gildner, Jean
Subject: Information request for BLA STN 125594

Importance: High

Dear Wouter,

We have the following requests for information for the BLA (STN 125594/0). Will you please provide a response by September 30, 2015?

1. Please provide the maximum number of cord blood units that may be processed per shift and per day.
2. Please describe what the components in the images Test #4 and Test #15 represent in Figure 4C-7 of the validations section of your submission. It is unclear what these images represent.
3. There appears to be a discrepancy in the validation of Duration of DMSO exposure and impact on HPC, Cord Blood (VAL-0022). According to the CMC section page 55, the segments and frozen units were thawed and tested after [REDACTED] frozen. In the validation section, page 34, the freezing bags and segments were stored for more than [REDACTED] prior to testing. Please justify this discrepancy and provide the actual time that the units and segments were frozen prior to testing.
4. In the CMC microbiology section of your submission figure 4A-12 shows a syringe presentation of the [REDACTED] solution. In the submission you have indicated that [REDACTED] solution is supplied by the manufacture in [REDACTED]. Please resolve this discrepancy and provide the details in a response.
5. In the validation report for frozen HPC, Cord Blood product integrity (VAL-0016) indicated that 87% of the barcodes matched and 3% of the units did not have a barcode attached to the canister. Please describe why 13% of the barcodes did not match and how 3% on the units did not have barcodes attached to the canister.
6. In facilities section of your submission, page 15, you have indicated the use for [REDACTED] and [REDACTED], but did not state what [REDACTED] is used for. Please indicate what [REDACTED] is used for in the manufacturing process for HPC, Cord Blood.
7. You have stated in the submission that validation for the distribution of frozen HPC, Cord Blood units in liquid nitrogen shipping containers would be completed during the 3rd quarter of 2015. Please provide the expected completion date for this validation or submit the completed

validation in your response.

8. A full validation report was not submitted for the validation of shipping container integrity. Additionally, please indicate if the testing in this validation was performed using the routine shipping configuration with worst-case conditions used.

Thank you, Lori
Lori Tull
Team Lead
Regulatory Management Staff
Office of Cellular, Tissue, and Gene Therapies
Center for Biologics Evaluation and Research
(240) 402-8361

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.